Bionano Genomics (BNGO) Accumulated Expenses (2017 - 2026)

Bionano Genomics has disclosed Accumulated Expenses across 10 years of filings, most recently posting $629000.0 for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $629000.0, down 84.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $629000.0 (down 84.02% YoY), and the FY2025 annual result was $561000.0, down 71.71% from the prior year.
• Accumulated Expenses came in at $629000.0 for Q1 2026 at Bionano Genomics, up from $561000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11.7 million in Q3 2022 to a low of $561000.0 in Q4 2025.
• The 5-year median for Accumulated Expenses is $7.8 million (2022), against an average of $6.7 million.
• Across the five-year window, Accumulated Expenses soared 91.8% in 2022 and slumped 84.02% in 2026, its largest moves.
• Bionano Genomics' Accumulated Expenses stood at $10.6 million in 2022, then slipped by 23.34% to $8.1 million in 2023, then plunged by 75.49% to $2.0 million in 2024, then plunged by 71.71% to $561000.0 in 2025, then advanced by 12.12% to $629000.0 in 2026.
• The last three Accumulated Expenses figures came in at $629000.0 (Q1 2026), $561000.0 (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.